We are live on
!
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$135M
1-Year Est. Return
80%
This Fund
S&P 500
This Quarter
Est. Return
+85.18%
1 Year Est. Return
+80%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$514K
(-0.38%)
Cap. Flow
-$34.4M
Cap. Flow
% of AUM
-25.43%
Top 10 Holdings %
Top 10 Hldgs %
89.83%
Holding
22
New
2
Increased
2
Reduced
2
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palisade Bio
PALI
|
+$8.65M |
| 2 |
Structure Therapeutics
GPCR
|
+$3.67M |
| 3 |
ADMA Biologics
ADMA
|
+$758K |
| 4 |
Praxis Precision Medicines
PRAX
|
+$323K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$11M |
| 2 |
NRXPW
NRX Pharmaceuticals Warrant
NRXPW
|
+$4.46M |
| 3 |
Apogee Therapeutics
APGE
|
+$945K |
| 4 |
GameSquare
GAME
|
+$170K |
| 5 |
Sight Sciences
SGHT
|
+$63.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.64% |
| 2 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ADMA Biologics
ADMA
$2.02B
| $44.8M | 33.1% |
2,457,542
+45,000
| +2% | +$758K |
|
|
CLLS
2
Cellectis
CLLS
$265M
| $15.9M | 11.73% |
3,281,501
| – | – |
|
|
3
Palisade Bio
PALI
$342M
| $10.6M | 7.81% |
+4,500,000
| New | +$8.65M |
|
4
Taysha Gene Therapies
TSHA
$1.71B
| $9.9M | 7.31% |
1,800,556
| – | – |
|
|
5
Praxis Precision Medicines
PRAX
$8.77B
| $9.8M | 7.23% |
33,237
+1,737
| +6% | +$323K |
|
|
6
Sight Sciences
SGHT
$274M
| $7.3M | 5.39% |
920,000
-10,000
| -1% | -$63.9K |
|
7
Zai Lab
ZLAB
$2.28B
| $7.06M | 5.21% |
400,000
| – | – |
|
|
8
Structure Therapeutics
GPCR
$3.45B
| $6.26M | 4.62% |
+90,000
| New | +$3.67M |
|
9
Assembly Biosciences
ASMB
$531M
| $5.98M | 4.41% |
175,706
| – | – |
|
10
Iovance Biotherapeutics
IOVA
$2.23B
| $4.09M | 3.02% |
1,500,000
| – | – |
|
11
Spyre Therapeutics
SYRE
$8.7B
| $3.28M | 2.42% |
100,000
| – | – |
|
12
Aura Biosciences
AURA
$723M
| $3.12M | 2.3% |
572,576
| – | – |
|
13
Ultragenyx Pharmaceutical
RARE
$2.88B
| $3.1M | 2.29% |
135,000
| – | – |
|
|
ORKA
14
Oruka Therapeutics
ORKA
$5.59B
| $2.27M | 1.68% |
75,000
| – | – |
|
|
15
Apogee Therapeutics
APGE
$10.1B
| $1.51M | 1.11% |
20,000
-15,000
| -43% | -$945K |
|
16
CALL
Replimune Group
REPL
$859M
| $486K | 0.36% |
50,000
| – | – |
|
|
AKRO
17
DELISTED
Akero Therapeutics
AKRO
| – | – |
-232,446
| Closed | -$11M |
|
|
18
GameSquare
GAME
$35.8M
| – | – |
-250,000
| Closed | -$170K |
|
19
Insmed
INSM
$23.5B
| – | – |
-158
| Closed | -$22.8K |
|
20
PUT
Eli Lilly
LLY
$1.05T
| – | – |
-22,500
| Closed | -$17.2M |
|
|
NRXPW
21
DELISTED
NRX Pharmaceuticals Warrant
NRXPW
| – | – |
-3,000,000
| Closed | -$4.46M |
|
22
PUT
NVIDIA
NVDA
$4.91T
| – | – |
-75,000
| Closed | -$14M |
|
Similar funds
UOP
ICM
EC
AV
FA
GEH
SA
SCM
B Group Inc's Q4 2025 Portfolio in Review
As of Q4 2025, B Group Inc held 22 positions worth $135M, down 0.38% from $136M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
B Group Inc withdrew a net $34.4M in Q4 2025, closing 6 positions and reducing 2 holdings. Its most notable exit was Akero Therapeutics, an estimated $11M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 74% a quarter earlier, followed by Communication Services.
Against the trend, B Group Inc opened a new position in Palisade Bio worth $10.6M.
- B Group Inc's largest Q4 2025 buy was Palisade Bio: 4,500,000 shares worth $10.6M.
- B Group Inc added most to ADMA Biologics in Q4 2025, an estimated $758K increase.
- B Group Inc's biggest Q4 2025 reduction was Apogee Therapeutics, cutting an estimated $945K.
- B Group Inc fully exited Akero Therapeutics in Q4 2025, selling an estimated $11M.
- B Group Inc's ten largest holdings make up 90% of its $135M portfolio in Q4 2025.
- B Group Inc opened 2 new positions and closed 6 in Q4 2025.
- B Group Inc's portfolio value fell 0.38% quarter-over-quarter to $135M.
Based on B Group Inc's 13F filing for Q4 2025, filed 17 Feb 2026.